Sigyn Therapeutics (SIGY) Common Equity (2016 - 2025)
Sigyn Therapeutics (SIGY) posted Common Equity of -$5.9 million for Q3 2025, down 8.82% sequentially from -$5.4 million in Q2 2025, and down 50.85% YoY from -$12.0 million in Q3 2024.
Sigyn Therapeutics (SIGY) Common Equity (2016 - 2025) Analysis & Trends
Sigyn Therapeutics has reported Common Equity for 10 years, with the latest figure at -$5.9 million in Q3 2025.
- Quarterly Common Equity fell 50.85% year-over-year to -$5.9 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was -$5.9 million (down 50.85% YoY) and the FY2024 annual result came in at -$4.5 million, down 30.63% from the prior year.
- Common Equity fell to -$5.9 million in Q3 2025 per SIGY's latest filing, from -$5.4 million in the prior quarter.
- Over five years, Common Equity peaked at $977137.0 in Q2 2021 and troughed at -$5.9 million in Q3 2025.
- A 5-year average of -$2.6 million and a median of -$3.0 million in 2023 frame the typical range for Common Equity.
- The sharpest annual moves came in 2021 and 2022: Common Equity jumped 617.73% in 2021, then tumbled 811.58% in 2022.
- Over 5 years, Common Equity stood at -$264584.0 in 2021, then plunged by 619.33% to -$1.9 million in 2022, then plunged by 79.3% to -$3.4 million in 2023, then plunged by 30.63% to -$4.5 million in 2024, then slumped by 32.74% to -$5.9 million in 2025.
- According to Business Quant data, Common Equity over the past three periods registered -$5.9 million, -$5.4 million, and -$4.9 million for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Sigyn Therapeutics | 48,161.31 | -37,409.69 | - | -5.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -5.92 Mn |
| Jun 30, 2025 | -5.44 Mn |
| Mar 31, 2025 | -4.95 Mn |
| Dec 31, 2024 | -4.46 Mn |
| Sep 30, 2024 | -3.92 Mn |
| Jun 30, 2024 | -3.67 Mn |
| Mar 31, 2024 | -4.02 Mn |
| Dec 31, 2023 | -3.41 Mn |
| Sep 30, 2023 | -3.58 Mn |
| Jun 30, 2023 | -3.04 Mn |
| Mar 31, 2023 | -2.35 Mn |
| Dec 31, 2022 | -1.90 Mn |
| Sep 30, 2022 | -1.74 Mn |
| Jun 30, 2022 | -1.18 Mn |
| Mar 31, 2022 | -731,569.00 |
| Dec 31, 2021 | -264,584.00 |
| Sep 30, 2021 | 358,232.00 |
| Jun 30, 2021 | 977,137.00 |
| Mar 31, 2021 | -80,253.00 |
| Dec 31, 2020 | 99,179.00 |